Floatz logo

azd7503

NASH

AstraZenecaPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the NASH cohort.

Asset / SponsorPhaseRating
Rosuvastatin
Beni-Suef University
Phase 4BBB
Arachidyl amido cholanoic acid
Galmed Pharmaceuticals Ltd
Phase 3BB
Alg-055009
Aligos Therapeutics
Phase 2BB
Elobixibat
Yokohama City University
Phase 2B
DYNAMOS
Yale University
Phase 2B

View all 22 →

Same molecule, other indications

azd7503 is also rated in:

Fatty Liver, NonalcoholicDormant
CC
Indicative ·
47 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CC
Indicative ·
46 / 100
View asset →
SteatohepatitisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →